Generic Name and Formulations:
Olopatadine (as HCl) 0.6% (665mcg/spray); aqueous nasal spray; contains benzalkonium chloride.
Alcon Laboratories, Inc.
Indications for PATANASE:
Seasonal allergic rhinitis.
2 sprays in each nostril twice daily.
<6yrs: not recommended. 6–11yrs: 1 spray in each nostril twice daily.
Other nasal diseases: not recommended. Avoid eyes. Monitor for nasal mucosal changes. Discontinue if nasal ulceration develops. Pregnancy (Cat.C). Nursing mothers.
Potentiates CNS depression with alcohol, other CNS depressants.
Bitter taste, headache, epistaxis, throat pain, post-nasal drip, cough, UTIs, nasal ulceration, nasal septal perforation, somnolence; children also: upper respiratory tract infection, pyrexia, rash.
Nasal spray pump—30.5g (240 sprays)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML
- Nicotinamide and Cancer
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma